Navigation Links
Hard To Treat Diseases (HTDS) Completes E Europe Merger
Date:1/5/2009

CLEARWATER, FL, Jan. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Further to the company's various merger updates where amongst other things the company addressed several targeted merger candidates, the company is pleased to announce that it has finalized its bilateral negotiations with Slavica Bio Chem, www.slavicabiochem.com (Slavica).

Slavica Bio Chem is a spin off of Renuyu Biochem, a USA and a UK company, founded by Andrea Zecevic. Andrea currently acts as a head scientific advisor to HTDS. The company research and development dates back to 2005. The institute and the physical plant is located in Belgrade Serbia. The company has been completely self funding with private resources since its inception. Over the next several weeks Slavica management and its officers intend to provide a series of filings and updates on the company's efforts and progress in this field.

Under the agreement the medical team will receive payment in stock and options on HTDS security on a delivery and performance based schedule. Consideration for Slavica is 300 million non-dilatable restricted shares to be distributed amongst all doctors involved in Belgrade Serbia research. Andrea Zecevic, as a vote of confidence in Slavica and who spearheaded the transaction, shall receive no stock in this transaction and in lieu will take stock options at a .03c strike price for up to 9% of the company common stock.

In other corporate news, the company representatives intend to visit mainland China for a second merger company discussions with a China based company in a similar field and research as Slavica with a significant operations already in place in China. Upon completion of the China merger, the company intends to name its new CEO, officers and directors consisting primarily of medical professionals and business consultants.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For scientific dialogue and inquiry only contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com

CONTACT: For scientific dialogue and inquiry only contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Molecular imaging enables earlier, individualized treatment of thyroid cancer
2. Family history of prostate cancer does not affect some treatment outcomes
3. Errors involving medications common in outpatient cancer treatment
4. Hard To Treat Diseases (HTDS) Operational Update
5. Cancer drug effectively treats transplant rejections
6. Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert
7. Treating gum disease linked to lower medical costs for patients with diabetes
8. Study: How Can States Treat a Sick Economy? Call the Doctors
9. Groundbreaking, inexpensive, pocket-sized ultrasound device can help treat cancer, relieve arthritis
10. Holiday Treats and Decorations Can Be a Deadly Combination for Pets
11. New study shows that a cough medicine ingredient could effectively treat prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: